Proteomics

Dataset Information

0

Evaluation of the activity of monensin and its analogs in triple negative breast cancer cells

ABSTRACT: This project aimed to identify key proteins dysregulated by monensin and itssynthetic analog, compound 12, in the triple-negative breast cancer (TNBC) cell line MDA-MB-231. Byanalyzing the molecular changes induced by these compounds, the study sought to elucidate themechanisms underlying their cytotoxic effects on breast cancer cells. Additionally, it explored potentialdifferences in the activity and efficacy of monensin and compound 12, providing critical insights into theirdistinct biological impacts. These findings may contribute to the development of targeted therapeuticstrategies for triple-negative breast cancer, a highly aggressive and treatment-resistant subtype of breastcancer

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Kalyani Dhusia  

LAB HEAD: Alicja Urbaniak, M.Sc., Ph.D., Ph.D.

PROVIDER: PXD060697 | Pride | 2026-03-30

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
ExperimentMaxQuant_lysatefromUrbaniakA_070822_prot_SF0117others.MGF Mgf
ExperimentMaxQuant_lysatefromUrbaniakA_070822_prot_SF0117others.mzid Mzid
ExperimentMaxQuant_phosphofromUrbaniak_070822_phos_SF0117others.MGF Mgf
ExperimentMaxQuant_phosphofromUrbaniak_070822_phos_SF0117others.mzid Mzid
UniProt_2022_02_Homo_sapiens_UP000005640.fasta Fasta
Items per page:
1 - 5 of 43
altmetric image

Publications

Monensin (<b>MON</b>) is a polyether ionophore antibiotic of natural origin and is an FDA-approved drug for veterinary use. Recent studies have highlighted its potential anticancer activity in various <i>in vitro</i> and <i>in vivo</i> models. In this study, we evaluated the anti-breast cancer activity of <b>MON</b> and 37 synthetic analog compounds using cell monolayer and organoid models. Through a mini-ring cell viability assay, several compounds were identified that were more potent and sele  ...[more]

Similar Datasets

Proteomics Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer
2021-06-24 | PXD025238 | Pride
Proteomics Proteomic and Phosphoproteomic Analysis of Pediatric Familial Adenomatous Polyposis
2026-04-27 | PXD061190 | Pride
Proteomics Phosphoproteomics analysis of PC-12 cells stimulated with IGF-1 for 30 minutes
2026-02-02 | PXD067358 | Pride
Proteomics DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells
2021-12-21 | PXD026352 | Pride
Proteomics Parallel kinase pathways stimulate actin polymerization at depolarized mitochondria
2022-03-15 | PXD031699 | Pride
Proteomics Phosphoproteomics provides novel insights into the response of primary acute lymphoblastic leukemia cells to microtubule depolymerization in G1 phase of the cell cycle
2021-12-30 | PXD027190 | Pride
Proteomics ProteoViz: A toolset for interactive analysis of phosphoproteomics data
2020-05-07 | PXD015606 | Pride
Proteomics The murine metastatic microenvironment of experimental brain metastases in breast cancer differs by host age in vivo: A proteomic study.
2024-01-11 | PXD042346 | Pride
Transcriptomics High-throughout sequencing of triple negative breast cancer cells treated actived compound D16
2021-08-17 | GSE182063 | GEO
Proteomics A common cell state in Triple Negative Breast Cancers can be targeted through inhibition of Spleen Tyrosine Kinase (SYK)
2016-06-15 | PXD001680 | Pride